USD10
ZNTL Shares
About Zentalis PharmaceuticalsZentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
USD10
ZNTL Shares
About Zentalis PharmaceuticalsZentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
Stats
TRADING WINDOW
Closed
OPENS AT
Aug 7 at 1:30 PM GMT+0
MARKET CAP
$351.66M
OPEN PRICE
Not enough data
LOW (1Y)
$1.21
HIGH (1Y)
$6.95
LOW (24H)
$4.79
HIGH (24H)
$5.11
VOLUME (24H)
$28.56K
95.93%
Price history
Time | Price | Change |
|---|---|---|
Today | Not enough data | Not enough data |
1 Day | $4.95 | |
1 Week | $4.80 | |
1 Month | $4.59 | |
1 Year | $1.44 |
Past performance is not a reliable indicator of future results.
Discover more
Popular cryptocurrencies
Popular prediction markets
Popular price predictions
Legal
Information is provided for informational purposes only, and is not investment advice. This is not an invitation, inducement or recommendation to buy any particular asset, or to employ any particular investment strategy. Coinbase makes no representation as to the accuracy, suitability or validity of any information provided.All ticker names are trademarks of their respective holders. Any ticker reference does not imply affiliate with or endorsement by a third-party. Real-time prices are sourced from third parties, but not from all markets. Source: Nasdaq Last Sale. Morningstar data ©2026.